Dogwood Q2 2026: Halneuron Phase 2b enrollment complete at 217, top-line on track for fall 2026

What happened

Dogwood Therapeutics announced its Q2 2026 financial results, highlighting completion of enrollment in the Halneuron Phase 2b trial (HALT-CINP-203) with 217 patients, and top-line data still expected in fall 2026. The news is positive on clinical execution, but the company did not provide an update on its cash position, burn rate, or whether the going-concern language from earlier filings has been resolved. Recall that as of the 2025 10-Q, Dogwood disclosed substantial doubt about its ability to continue as a going concern and only had cash through Q1 2026, necessitating the January 2026 financing and a stockholder vote on warrant issuance. The master report's WAIT rating was driven by that financing uncertainty, and today's release does not address whether the required approvals were obtained or if additional capital was secured. Investors should treat this as a clinical milestone update rather than a full de-risking of the capital-structure problem.

Implication

The completion of enrollment reduces clinical execution risk but does not eliminate the binary nature of the Phase 2b outcome or the capital-structure overhang. Without an update on cash and going concern, the stock remains a lottery ticket on both the clinical readout and the company's ability to fund operations through that readout. The master report's attractive entry of $2.60 and trim above $4.75 are still relevant, but the current price of around $3 (as of last known) sits in the middle, offering poor risk-reward until financials are clarified. Any new financing announcement, especially at a discount, could further dilute existing holders and cap upside. The next 10-Q filing will be critical: if it shows extended runway past the fall 2026 readout without heavily dilutive terms, the thesis could shift to a buy; if not, the WAIT should remain.

Thesis delta

The thesis remains a WAIT, but clinical de-risking has slightly improved the probability of a positive outcome. The prior concern was financing to reach the data; with enrollment complete and top-line timing reaffirmed, that concern is now more acute because the company must still fund the final analysis period. The lack of financial disclosure in this release means the core uncertainty—cash runway and dilution—persists, and the thesis does not change until that is addressed.